Quest Diagnostics Stock (DGX): It Beat, RAISED Guidance, and Broke Out — Why We Say BUY

Quest Diagnostics (DGX) Q2 2026 — Quest Diagnostics (DGX), one of the two national giants of U.S. lab testing, reported a strong Q2 2026: adjusted EPS of $3.12 beat the ~$2.82 estimate (+19.1% YoY) on revenue of $3.04B (+10.2%), with 10.0% ORGANIC growth; reported GAAP EPS was $2.84 (+15%). The engine was pure volume — requisitions rose 13.1% (organic +13.0%) — while revenue per requisition fell 2.8%, so adjusted operating margin slipped to 16.5% (from 16.9%). Management RAISED full-year 2026 guidance again — adjusted EPS to $11.05–$11.25, revenue to $11.95–$12.05B, and operating cash flow to ~$1.80B. The stock jumped ~8.6% on the print to a fresh 52-week high (~$238 intraday), closing near $228, up from a $166 low. At ~20x forward EPS, our owner-earnings DCF lands fair value near $250 — above the price and above the Street's ~$232 Hold target. Our call: BUY, 4/5. Quest Diagnostics is the boring, defensive backbone of American lab testing — a ~$25B company that runs the blood, urine, and molecular tests your doctor orders, serving half of U.S. physicians and hospitals and one in three adults a year, led by CEO Jim Davis. For years the market has treated it as a slow, low-growth compounder that buys its growth by acquiring smaller labs. Q2 2026 quietly challenged that: adjusted EPS of $3.12 beat the ~$2.82 estimate (+19.1% YoY), revenue rose 10.2% to $3.04B — and critically, 10.0% of that was ORGANIC, from the existing business, not deals. Test volume (requisitions) jumped 13.1% (organic +13.0%) across physician, hospital, and consumer channels, with double-digit gains in high-value Advanced Diagnostics (Alzheimer's AD-Detect blood tests, Haystack MRD molecular cancer testing, cardiometabolic panels). Management RAISED full-year guidance again — adj EPS to $11.05–$11.25, revenue to $11.95–$12.05B, OCF to ~$1.80B — and the stock popped ~8.6% to a new 52-week high near $228. The honest catch: it's ALL volume — revenue per requisition fell 2.8% and adjusted operating margin slipped to 16.5% from 16.9%, so automation and AI (robotics in screening, smart specimen routing) must cut cost per test faster than reimbursement cuts price. On owner earnings of ~$1.25B/yr (FCF ≈ adjusted net income), our DCF lands fair value near $250 — about 10% above the ~$228 price — and, crucially, even the conservative steady-growth path lands ~$232, right at today's price, so the downside is protected. That's above the Street's lukewarm ~$232 Hold target (roughly 13 buys / 18 holds / 3 sells). Our call: BUY, 4/5 — a quality, defensive compounder growing double digits at ~20x earnings, and we're more bullish than Wall Street. We'd scale in after the pop and add on any dip toward the low $200s, watching organic volume and the operating margin every quarter. Not financial advice. THE CALL: BUY (4/5, THE 'SLEEPY LAB' IS QUIETLY COMPOUNDING — 10% ORGANIC GROWTH, A RAISED GUIDE, AND STILL PRICED NEAR 20x EARNINGS) — base-case value ~$250 vs ~$228 today. What to watch: hard evidence that automation and mix are converting the volume surge into profit — adjusted operating margin turning back up while organic volume stays strong — which would prove the acceleration is durable and push our fair value higher; the risk to respect is a step-down in reimbursement or the volume surge fading so revenue per requisition keeps falling with nothing to offset it, capping earnings and the multiple. Watch two numbers every quarter: organic requisition volume and the adjusted operating margin. Also on YouTube: @ChargedAlpha DISCLAIMER: For informational and educational purposes only. Not financial advice. Do your own research before any investment decision.